DR-01 for T-Cell Lymphoma
Study Summary
This trial is testing a new drug, DR-01, to treat adults with large granular lymphocytic leukemia or cytotoxic lymphomas. The goal is to see if it is safe and effective.
- T-Cell Lymphoma
- Cutaneous T-Cell Lymphoma
- Mycosis Fungoides
- Hepatosplenic T-cell Lymphoma
- Natural Killer Cell Leukemia
- Systemic T-cell Lymphoma
- Nasal Lymphoma
- Intestinal T-Cell Lymphoma
- CD8+/NK Cell Lymphoma
- Large Granular Lymphocytic Leukemia
- Hydroa Vacciniforme-Like Lymphoproliferative Disorder
- Chronic Lymphoproliferative Disorder of the Gastrointestinal Tract
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
What is the total enrollment of participants for this clinical research?
"Affirmative. Clinicaltrials.gov provides evidence that this medical trial is presently recruiting and has been since 13 July 2022, with the latest update on 6 September of the same year. 69 patients need to be sourced from 8 sites."
How many establishments are carrying out this trial?
"Currently, this research study is actively recruiting patients from 8 locations across the United States; these include Columbus, Fairfax and Houston among other cities. To reduce travel burden associated with enrolment it is wise to select a site closest to you."
Are there opportunities for enrolment in this research framework?
"Affirmative. The clinicaltrials.gov platform shows that this medical experiment is presently recruiting, having been initially posted on July 13th 2022 and last updated September 6th 2022. A total of 69 patients are needed across 8 sites for the trial to reach completion."